130 related articles for article (PubMed ID: 38358204)
1. Diagnostic utility of LMO2 immunohistochemistry in distinguishing T-lymphoblastic leukemia/lymphoma from thymoma.
Bansal D; Pasricha S; Gupta G; Sharma A; Durga G; Kamboj M; Mehta A
Indian J Pathol Microbiol; 2024; 67(1):141-144. PubMed ID: 38358204
[TBL] [Abstract][Full Text] [Related]
2. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.
Jevremovic D; Roden AC; Ketterling RP; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2016 Feb; 145(2):180-90. PubMed ID: 26796495
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Utility of the Germinal Center-associated Markers GCET1, HGAL, and LMO2 in Hematolymphoid Neoplasms.
Menter T; Gasser A; Juskevicius D; Dirnhofer S; Tzankov A
Appl Immunohistochem Mol Morphol; 2015 Aug; 23(7):491-8. PubMed ID: 25203428
[TBL] [Abstract][Full Text] [Related]
4. LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations.
Brar N; Butzmann A; Kumar J; Peerani R; Morgan EA; Grigoriadis G; Kumar B; Tatarczuch RM; Warnke RA; Ohgami RS
Histopathology; 2020 Dec; 77(6):984-988. PubMed ID: 32526041
[TBL] [Abstract][Full Text] [Related]
5. NOTCH1 intracellular domain immunohistochemistry as a diagnostic tool to distinguish T-lymphoblastic lymphoma from thymoma.
Jegalian AG; Bodo J; Hsi ED
Am J Surg Pathol; 2015 Apr; 39(4):565-72. PubMed ID: 25517959
[TBL] [Abstract][Full Text] [Related]
6. ERG Expression is Helpful in Differentiating T-Lymphoblastic Lymphoma from Thymoma.
Huang W; Zhang W; Zeng L; Liao S; Liu F; Li L
Int J Surg Pathol; 2023 Apr; 31(2):137-141. PubMed ID: 35435050
[TBL] [Abstract][Full Text] [Related]
7. Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.
Shields BJ; Alserihi R; Nasa C; Bogue C; Alexander WS; McCormack MP
Leukemia; 2015 Apr; 29(4):927-38. PubMed ID: 25283843
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels.
Miyashita K; Kitajima K; Goyama S; Kitamura T; Hara T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2310-2316. PubMed ID: 29278703
[TBL] [Abstract][Full Text] [Related]
9. T-cell lymphoblastic leukemia/lymphoma presenting in a recurrent thymoma.
Macon WR; Rynalski TH; Swerdlow SH; Cousar JB
Mod Pathol; 1991 Jul; 4(4):524-8. PubMed ID: 1924284
[TBL] [Abstract][Full Text] [Related]
10. Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody.
Agostinelli C; Paterson JC; Gupta R; Righi S; Sandri F; Piccaluga PP; Bacci F; Sabattini E; Pileri SA; Marafioti T
Histopathology; 2012 Jul; 61(1):33-46. PubMed ID: 22394247
[TBL] [Abstract][Full Text] [Related]
11. Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL.
McCormack MP; Shields BJ; Jackson JT; Nasa C; Shi W; Slater NJ; Tremblay CS; Rabbitts TH; Curtis DJ
Blood; 2013 Sep; 122(12):2093-103. PubMed ID: 23926305
[TBL] [Abstract][Full Text] [Related]
12. T-Lymphoblastic Leukemia/Lymphoma and Thymoma: A Case Report and Review of the Literature of a Rare Association.
Mizrahi N; Kugler E; Hayman L; Yeshurun M; Grossman A; Raanani P; Wolach O
Acta Haematol; 2022; 145(1):106-111. PubMed ID: 34537764
[TBL] [Abstract][Full Text] [Related]
13. Concurrent thymoma, thymic carcinoma, and T lymphoblastic leukemia/lymphoma in an anterior mediastinal mass.
Ito J; Yoshida A; Maeshima AM; Nakagawa K; Watanabe S; Kobayashi Y; Fukuhara S; Tsuta K
Pathol Res Pract; 2015 Sep; 211(9):693-6. PubMed ID: 26150396
[TBL] [Abstract][Full Text] [Related]
14. ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms.
Goossens S; Wang J; Tremblay CS; De Medts J; T'Sas S; Nguyen T; Saw J; Haigh K; Curtis DJ; Van Vlierberghe P; Berx G; Taghon T; Haigh JJ
Haematologica; 2019 Aug; 104(8):1608-1616. PubMed ID: 30679322
[TBL] [Abstract][Full Text] [Related]
15. Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.
Li L; Mitra A; Cui K; Zhao B; Choi S; Lee JY; Stamos DB; El-Khoury D; Warzecha C; Pfeifer K; Hardwick J; Zhao K; Venters B; Davé UP; Love PE
Blood; 2020 Jun; 135(25):2252-2265. PubMed ID: 32181817
[TBL] [Abstract][Full Text] [Related]
16. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.
Latchmansingh KA; Wang X; Verdun RE; Marques-Piubelli ML; Vega F; You MJ; Chapman J; Lossos IS
Mod Pathol; 2022 Sep; 35(9):1220-1226. PubMed ID: 35322192
[TBL] [Abstract][Full Text] [Related]
17. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia.
Chilosi M; Doglioni C; Yan Z; Lestani M; Menestrina F; Sorio C; Benedetti A; Vinante F; Pizzolo G; Inghirami G
Am J Pathol; 1998 Jan; 152(1):209-17. PubMed ID: 9422538
[TBL] [Abstract][Full Text] [Related]
19. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal.
McCormack MP; Young LF; Vasudevan S; de Graaf CA; Codrington R; Rabbitts TH; Jane SM; Curtis DJ
Science; 2010 Feb; 327(5967):879-83. PubMed ID: 20093438
[TBL] [Abstract][Full Text] [Related]
20. Thymoma with loss of keratin expression (and giant cells): a potential diagnostic pitfall.
Adam P; Hakroush S; Hofmann I; Reidenbach S; Marx A; Ströbel P
Virchows Arch; 2014 Sep; 465(3):313-20. PubMed ID: 24923897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
